UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 1)*

 

ALX Oncology Holdings Inc.

(Name of Issuer)

 

Common stock, par value $0.001 per share

(Title of Class of Securities)

 

00166B105

(CUSIP Number)

 

September 30, 2024

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐

Rule 13d-1(b)

 

☒

Rule 13d-1(c)

 

☐

Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 00166B105
1	NAMES OF REPORTING PERSONS
	Vivo Capital Fund IX, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)
	(a)    ☐
	(b)    ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER
		1,813,864(1)
	6	SHARED VOTING POWER
		0
	7	SOLE DISPOSITIVE POWER
		1,813,864(1)
	8	SHARED DISPOSITIVE POWER
		0

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,813,864(1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	3.4% (2)
12	TYPE OF REPORTING PERSON  (See Instructions)
	PN

 

(1)	The shares of common stock, par value $0.001 per share (the “Common Stock”) of ALX Oncology Holdings Inc. (the “Issuer”) are held of record by Vivo Capital Fund IX, L.P, as of November 8, 2024.Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

 

(2)	Based on 52,743,104 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on November 7, 2024.

 

 

CUSIP No. 00166B105
1	NAMES OF REPORTING PERSONS
	Vivo Capital IX, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)
	(a)    ☐
	(b)    ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER
		1,813,864(1)
	6	SHARED VOTING POWER
		0
	7	SOLE DISPOSITIVE POWER
		1,813,864(1)
	8	SHARED DISPOSITIVE POWER
		0

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,813,864(1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	3.4 % (2)
12	TYPE OF REPORTING PERSON  (See Instructions)
	OO

 

(1)	The shares of Common Stock of the Issuer are held of record by Vivo Capital Fund IX, L.P. as of November 8, 2024. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

 

(2)

Based on 52,743,104 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on November 7, 2024.

 

 

CUSIP No. 00166B105
1	NAMES OF REPORTING PERSONS
	Vivo Opportunity Fund Holdings, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)
	(a)    ☐
	(b)    ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER
		0 (1)
	6	SHARED VOTING POWER
		0
	7	SOLE DISPOSITIVE POWER
		0 (1)
	8	SHARED DISPOSITIVE POWER
		0

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	0 (1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	0 % (2)
12	TYPE OF REPORTING PERSON  (See Instructions)
	PN

 

 

CUSIP No. 00166B105
1	NAMES OF REPORTING PERSONS
	Vivo Opportunity, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)
	(a)    ☐
	(b)    ☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER
		0 (1)
	6	SHARED VOTING POWER
		0
	7	SOLE DISPOSITIVE POWER
		0 (1)
	8	SHARED DISPOSITIVE POWER
		0

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	0 (1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	0 % (2)
12	TYPE OF REPORTING PERSON  (See Instructions)
	OO

 

 

Item 1. (a)

Name of Issuer:

 

ALX Oncology Holdings Inc.

 

(b)

Address of Issuer’s Principal Executive Offices:

 

323 Allerton Avenue

 

South San Francisco, California 94080

 

Item 2. (a)

Name of Person Filing:

 

Vivo Capital Fund IX, L.P. and its General Partner Vivo Capital IX, LLC

 

Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC

 

(b)

Address of Principal Business Office or, if None, Residence:

 

192 Lytton Avenue, Palo Alto, CA 94301

 

(c)

Citizenship:

 

Vivo Capital Fund IX, L.P. is a Delaware limited partnership.

 

Vivo Capital IX, LLC is a Delaware limited liability company.

 

Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership

 

Vivo Opportunity, LLC is a Delaware limited liability company.

 

(d)

Title of Class of Securities:

 

Common stock, par value $0.001 per share

 

(e)

CUSIP Number:

 

00166B105

 

Item 3.

If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

 

(a)

☐

Broker or dealer registered under Section 15 of the Act.

(b)

☐

Bank as defined in Section 3(a)(6) of the Act.

(c)

☐

Insurance company as defined in Section 3(a)(19) of the Act.

(d)

☐

Investment company registered under Section 8 of the Investment Company Act of 1940.

(e)

☐

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

☐

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

☐

A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);

(h)

☐

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

(i)

☐

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

(j)

☐

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)

☐

Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

 

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

 

Not Applicable.

 

 

Item 4.

Ownership.

 

(a)

Amount beneficially owned:

 

The 1,813,864 shares of Common Stock are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

 

(b)

Percent of class:

 

Vivo Capital Fund IX, L.P. 3.4 %

 

Vivo Capital IX, LLC: 3.4%

 

Vivo Opportunity Fund Holdings, L.P.: 0%

 

Vivo Opportunity, LLC: 0%

 

(c)

Number of shares as to which such person has:

 

(i)

Sole power to vote or to direct the vote:

 

Vivo Capital Fund IX, L.P.: 1,813,864 shares

 

Vivo Capital IX, LLC: 1,813,864 shares

 

Vivo Opportunity Fund Holdings, L.P.: 0 share

 

Vivo Opportunity, LLC: 0 share

 

(ii)

Shared power to vote or to direct the vote: 0

 

(iii)

Sole power to dispose or to direct the disposition of:

 

Vivo Capital Fund IX, L.P.: 1,813,864 shares

 

Vivo Capital IX, LLC: 1,813,864 shares

 

Vivo Opportunity Fund Holdings, L.P.: 0 share

 

Vivo Opportunity, LLC: 0 share

 

(iv)

Shared power to dispose of or to direct the disposition of: 0

 

 

Item 5.

Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not Applicable.

 

Item 8.

Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.

Notice of Dissolution of Group.

 

Not applicable.

 

Item 10.

Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

		Vivo Capital Fund IX, L.P.
		By: Vivo Capital IX, LLC, its General Partner
		November 14, 2024
		(Date)
		/s/ Frank Kung
		(Signature)
		Managing Member
		(Title)
		Vivo Capital IX, LLC
		November 14, 2024
		(Date)
		/s/ Frank Kung
		(Signature)
		Managing Member
		(Title)
		Vivo Opportunity Fund Holdings, L.P.
		By: Vivo Opportunity, LLC, its General Partner
		November 14, 2024
		(Date)
		/s/ Kevin Dai
		(Signature)
		Managing Member
		(Title)
		Vivo Opportunity, LLC
		November 14, 2024
		(Date)
		/s/ Kevin Dai
		(Signature)
		Managing Member
		(Title)

 

 

EXHIBIT INDEX

 

Exhibit
99.1		Joint Filing Statement

 

 

Exhibit 99.1

 

JOINT FILING AGREEMENT

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believev that such information is inaccurate.

 

		Vivo Capital Fund IX, L.P.
		By: Vivo Capital IX, LLC, its General Partner
		November 14, 2024
		(Date)
		/s/ Frank Kung
		(Signature)
		Managing Member
		(Title)
		Vivo Capital IX, LLC
		November 14, 2024
		(Date)
		/s/ Frank Kung
		(Signature)
		Managing Member
		(Title)
		Vivo Opportunity Fund Holdings, L.P.
		By: Vivo Opportunity, LLC, its General Partner
		November 14, 2024
		(Date)
		/s/ Kevin Dai
		(Signature)
		Managing Member
		(Title)
		Vivo Opportunity, LLC
		November 14, 2024
		(Date)
		/s/ Kevin Dai
		(Signature)
		Managing Member
		(Title)